- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03207646
Smartphone GUIded MeDication AdherencE and Rehabilitation in Patients With Coronary Artery Disease (smartGUIDE)
Smartphone GUIded MeDication AdherencE and Rehabilitation in Patients With Coronary Artery Disease (smartGUIDE)
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Stanford, California, Estados Unidos, 94305
- Stanford Healthcare
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria:
I. ≥ 18 years of age
II. Patient at Stanford Health Care with evidence of CAD (atherosclerosis of one or more coronary arteries or clinical evidence or documentation of ischemia, infarction) OR a diagnosis related to CAD (i.e. ischemic heart disease ICD-10-Code: I20-25).
III. Prescription of a P2Y12 antagonist and/or a statin for an anticipated duration of at least 3 months following discharge
IV. Possession of a compatible (iPhone 5s or later; OS 8.1 or higher) smartphone with an active phone number and data plan. The smartphone must be in continued possession of the participant. It may not be a shared device and must exclusively remain in the possession of the participant during the study period. The smartphone must have an active cellular phone number and cellular data subscription. Wi-Fi internet capability is not a substitute for an active cellular data plan.
V. Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.
VI. Willing to have the mobile application installed on a smartphone and use it every day during the entire study period VII. Willing to provide oral confirmation indicating that he/she is currently not using a medication adherence application.
VIII. Ability to read and understand English.
Exclusion criteria:
Any potential participant who meets any of the following criteria will be excluded from participating in the study:
I. Anticipated inability to adhere to the mobile application (BrightHeart®) based on opinion of site Principal Investigator (PI).
II. Current use of adherence tracking devices, electronic, smartphone or computer applications, including but not limited to smart pill bottles, pill timers, radiofrequency tagged medications or dispensers, mobile applications, or automated phone reminders. Pill organizers that remind participants when to take medicine with beeps or alerts are exclusion.
a. Note: Pharmacy and health care plan automated refill reminders are permitted and are not exclusion. Pill organizers or containers that only compartmentalize a participant's medications based on days of the week are not exclusion.
III. Cognitive, visual, hearing, voice, or motor impairment that would prevent completion of study procedures or use of mobile phone. Co-morbidities that would preclude participation (e.g. ongoing chemotherapy) or planned hospitalization for complex procedures as determined by the PI (e.g. bypass, valve or aortic surgery, transarterial valve replacement) IV. End-stage of one of the following: heart failure (using left ventricular assist device or listed for heart transplantation), renal disease, lung disease, liver disease.
V. Any condition with a life expectancy less than 3 months. VI. Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator VII. Any other condition as determined by the PI.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: smartphone-based cardiac rehabilitation
The BrightHeart® mobile application is installed on the smartphone and a heart coach set up and guides the participant through a cardiac care program.
|
BrightHeart® has two components: smartphone mobile based application and a human coach.
It is a combined approach of medication adherence, exercise, diet, sleep and stress reduction.
|
Sin intervención: Control
Standard-of-care alone.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Medication adherence
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
The proportion of days coverd (PDC) expressed as a percentage but considered as a continuous variable of the composite of the prescribed P2Y12 receptor antagonist and/or the statin.
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Medication adherence II
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
Proportion of participants with PDC ≥ 80% of the composite of the P2Y12 receptor antagonist and/or the statin
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Medication adherence III
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
The PDC of each medication of the composite
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Medication adherence IV
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
Proportion of participants with PDC ≥ 80% of each of the composite
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Medication adherence V
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
Mean time from discharge to first fill
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Medication persistence
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
proportion of patients with an active prescription at three months of a statin and P2Y12 inhibitor
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Cardiovascular risk factors I
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
Serum LDL-C at End of Study
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Cardiovascular risk factors II
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
Proportion of participants within target blood pressure (<140/90 mmHg or <130/80 mmHg for patients with diabetes mellitus or chronic kidney disease) at End of Study
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Cardiovascular risk factors III
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
Proportion of participants with HbA1c ≤ 7% at End of Study (only if diabetes mellitus was known at time of inclusion)
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Cardiovascular risk factors IV
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
Change in body weight from baseline to End of Study
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Cardiovascular risk factors V
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
Change in quality of life (measured by EQ-5D-3L14) from day 3-10 after discharge to End of Study
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Cardiovascular risk factors VI
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
Change in patient activation (measured by PAM®1015) from day 3-10 after discharge to End of Study
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Cardiovascular risk factors VII
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
Physical activity at End of Study (measured by a physical acitivity questionnaire)
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Exploratory I: Rehospitalization
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
30-day rehospitalization for any reason
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Exploratory II: Cardiovascular outcomes
Periodo de tiempo: Baseline through End of Study visit - approximately 90 days per participant.
|
Major adverse cardiac events (MACE) defined as: Death, myocardial infarction, acute coronary syndrome, out of hospital cardiac arrest, stent thrombosis, repeat revascularization at 90 days
|
Baseline through End of Study visit - approximately 90 days per participant.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Minang (Mintu) Turakhia, MD, Stanford University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 39555
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre BrightHeart®
-
Dong-A ST Co., Ltd.TerminadoDispepsia funcionalCorea, república de
-
Chong Kun Dang PharmaceuticalTerminado
-
Chung-Ang University Hosptial, Chung-Ang University...DesconocidoDispepsia funcionalCorea, república de
-
University of MiamiBSN Medical IncReclutamiento
-
Amir AzarpazhoohInstitut Straumann AGTerminadoInflamación periodontal | Alargamiento de coronaCanadá
-
Novartis PharmaceuticalsTerminadoEnfermedad Pulmonar Obstructiva Crónica (EPOC)Argentina
-
GuerbetTerminadoTumor cerebral primarioColombia, Corea, república de, Estados Unidos, México
-
Coopervision, Inc.Terminado
-
Sanofi Pasteur, a Sanofi CompanyTerminadoTos ferina | Difteria | PolioEstados Unidos
-
Galderma R&DTerminadoDermatitis atópicaFilipinas, Porcelana